Zinc sulfate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1987
- First approval year
- 1987
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Zinc sulfate
- Molecular weight
- 161.45
- Structure (SMILES)
- O=S(=O)([O-])[O-].[Zn+2]
- pennine
- Pennine
- sootheye
- Sootheye
- white vitriol
- White vitriol
- z span
- Z span
- zinc sulfate
- Zinc sulfate
- zinc sulfate component of multrys
- Zinc sulfate component of multrys
- zinc sulfate component of tralement
- Zinc sulfate component of tralement
- zincfrin
- Zincfrin
- zincomed
- Zincomed
- zincosol
- Zincosol
- zindole
- Zindole
- zing
- Zing
- zn sulf co
And 1 more, listed on the interactive page.
- nsc 135806
- nsc 32677
- NSC-135806
- NSC-32677
- oral zinc sulphate tablets
- sulfuric acid zinc salt 1 1
- Sulfuric acid, zinc salt (1:1)
- Zinc (as sulfate)
- Zinc (as sulphate)
- zinc as sulfate
- zinc as sulphate
- zinc sulfate
- Zinc sulfate
- Zinc sulfate (1:1) heptahydrate
- Zinc sulfate (1:1) monohydrate
- Zinc sulfate (anhydrous)
- ZINC SULFATE [HSDB]
- ZINC SULFATE [MI]
- zinc sulfate 1 1 heptahydrate
- zinc sulfate 1 1 monohydrate
- zinc sulfate anhydrous
- Zinc sulfate anhydrous
- zinc sulfate hsdb
- zinc sulfate hydrate
- Zinc sulfate hydrate
And 30 more, listed on the interactive page.
- CAS registry numbers
- 7733-02-0
- ChEMBL ID
- CHEMBL1200929
- InChIKey
- NWONKYPBYAMBJT-UHFFFAOYSA-L
- PubChem compound IDs
- 24424
- FDA ingredient codes (UNII)
- 0J6Z13X3WO
- A12CB01
- B05XA18
Sources for recorded values
- 39954
- 1299928
- Applicant
- ABRAXIS PHARM
- Approval date
- 5 May 1987
- Application number
- NDA019229
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Parenteral
- Condition
- Infertility
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000545
- Subject identifier
- D007246
- Condition
- Folic Acid Deficiency
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001070
- Subject identifier
- D005494
- Condition
- Obesity
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Stomatitis, Aphthous
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003938
- Subject identifier
- D013281
- Condition
- Anemia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004272
- Subject identifier
- D000740
- Condition
- Hepatitis, Alcoholic
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001345
- Subject identifier
- D006519
- Condition
- Mucositis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001898
- Subject identifier
- D052016
- Condition
- Anemia, Iron-Deficiency
- Highest recorded phase
- 4
- Condition identifier
- HP:0001891
- Subject identifier
- D018798
- Condition
- Diarrhea
- Highest recorded phase
- 2
- Condition identifier
- HP:0002014
- Subject identifier
- D003967
- Condition
- Bronchiolitis
- Highest recorded phase
- 3
- Condition identifier
- HP:0011950
- Subject identifier
- D001988
- Condition
- Asthenozoospermia
- Highest recorded phase
- 2
- Condition identifier
- HP:0012207
- Subject identifier
- D053627
- Condition
- Sepsis
- Highest recorded phase
- 2
- Condition identifier
- HP:0100806
- Subject identifier
- D018805
- Condition
- Anemia, Sickle Cell
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0011382
- Subject identifier
- D000755
- Condition
- Hyperlipidemias
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0021187
- Subject identifier
- D006949
- Condition identifier
- EFO_0000545
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001070
- Condition identifier
- EFO_0001070
- Highest recorded phase
- 4
- Condition identifier
- EFO_0003106
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003938
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003965
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004272
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 4
- Condition identifier
- EFO_0006343
- Condition identifier
- EFO_0007450
- Condition identifier
- EFO_0008517
- Condition identifier
- EFO_0008572
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009909
- Condition identifier
- EFO_0010134
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000003
- Condition identifier
- EFO_1000003
- Highest recorded phase
- 4
- Condition identifier
- EFO_1000739
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000760
- Condition identifier
- EFO_1001898
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001904
- Condition identifier
- EFO_1001904
- Highest recorded phase
- 2
- Condition identifier
- HP_0000789
- Highest recorded phase
- 1
- Condition identifier
- HP_0000952
- Condition identifier
- HP_0001369
- Highest recorded phase
- 4
And 67 more, listed on the interactive page.
- Event
- abortion
- Reports
- 8
- Reporting signal score
- 23.4963
- Event
- abortion spontaneous
- Reports
- 15
- Reporting signal score
- 14.7515
- Event
- beta haemolytic streptococcal infection
- Reports
- 14
- Reporting signal score
- 61.6443
- Event
- breast cancer
- Reports
- 19
- Reporting signal score
- 29.3223
- Event
- candida infection
- Reports
- 11
- Reporting signal score
- 21.8748
- Event
- chronic sinusitis
- Reports
- 17
- Reporting signal score
- 64.208
- Event
- coma
- Reports
- 73
- Reporting signal score
- 185.58
- Event
- condition aggravated
- Reports
- 47
- Reporting signal score
- 31.5013
- Event
- congenital anomaly
- Reports
- 8
- Reporting signal score
- 18.1197
- Event
- copper deficiency
- Reports
- 14
- Reporting signal score
- 93.1844
- Event
- diastolic dysfunction
- Reports
- 9
- Reporting signal score
- 26.8941
- Event
- diverticulum
- Reports
- 9
- Reporting signal score
- 18.342
- Event
- drug hypersensitivity
- Reports
- 33
- Reporting signal score
- 12.5901
- Event
- drug intolerance
- Reports
- 28
- Reporting signal score
- 25.6322
- Event
- embolism venous
- Reports
- 9
- Reporting signal score
- 26.1343
- Event
- emphysema
- Reports
- 10
- Reporting signal score
- 25.8059
- Event
- fat embolism
- Reports
- 2
- Reporting signal score
- 10.0473
- Event
- female genital tract fistula
- Reports
- 16
- Reporting signal score
- 69.3682
- Event
- gastric ulcer perforation
- Reports
- 3
- Reporting signal score
- 12.9078
- Event
- gastrooesophageal reflux disease
- Reports
- 83
- Reporting signal score
- 211.598
- Event
- granulomatous liver disease
- Reports
- 2
- Reporting signal score
- 8.37148
- Event
- hepatic cirrhosis
- Reports
- 17
- Reporting signal score
- 36.8788
- Event
- hepato-lenticular degeneration
- Reports
- 3
- Reporting signal score
- 15.329
- Event
- hiatus hernia
- Reports
- 10
- Reporting signal score
- 19.9137
- Event
- hidradenitis
- Reports
- 10
- Reporting signal score
- 30.7455
And 44 more, listed on the interactive page.
- NCT00142285
- NCT00252304
- NCT03690583
- NCT00355043
- NCT01015183
- NCT06482034
- NCT01140074
- NCT01162109
- NCT05366595
- NCT01210014
- NCT01809132
- NCT02217189
- NCT02985905
- NCT02335593
- NCT02516475
- NCT04301336
- NCT05178953
- NCT05395143
- Dose
- Small amount
- How often
- 1 to 3 times daily
Conditions of use
- May be covered with a sterile bandage
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 6
- Molecular formula
- O4SZn
- Monoisotopic mass
- 159.880871
- Natural product
- No
- 61480-137
- Recorded assays
- 23
- Active assays
- 0
- Astringents
Related records
Trials (196)
- A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
- A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
- A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder
- A Clinical Trial of PRAX-114 in Participants With Essential Tremor
- A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
- A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery
- A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers
- A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
- A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
- A Phase I Study of MSB2311 in Advanced Solid Tumors
- A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
- A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)
- A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
- A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
- A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects
- A Randomized Controlled Trial Evaluating Different Doses of Oral Zinc Supplementation in Combination With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
- A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
- A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
- A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain
Approved for (2)
- Anemia
- Iron deficiency anemia
In development for (11)
- Alcoholic hepatitis Phase 2
- Bronchiolitis Phase 3
- Canker sore Phase 2
- Chronic kidney disease Phase 2
- Diarrheal disease Phase 2
- Hyperlipidemia Phase 2
- Infertility disorder Early phase 1
- Mucositis Phase 2
- Obesity disorder Phase 2
- Pneumonia Phase 3
- Sickle cell disease Phase 2
Other linked conditions (5)
- Acute diarrhea
- Chronic periodontitis
- Major depressive disorder
- Poliomyelitis
- Rosacea